19.07.2022 • Newsimmunotherapy

ABL Inks Immunotherapeutics Pact with KaliVir

US-based ABL, which bills itself as a pure play CDMO specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, is partnering with KaliVir Immunotherapeutics on oncolytic viruses.

Specifically, ABL will manufacture KaliVir’s oncolytic viruses for that company’s upcoming clinical trial. The privately held Pennsylvania-based biotech develops and maintains oncolytic viral immunotherapy programs.

ABL said the pact, for which financial terms have not been disclosed, will allow it to strengthen its new fixed-bed bioreactor platform and develop a new generation of oncolytic viruses. The CDMO will provide KaliVir with material to perform its first-in-human clinical study with oncolytic vaccinia virus derived from its proprietary Vaccinia Enhanced Template (VET) platform and make progress toward supplying unmet needs.

At the same time, the partnership is expected to boost the Maryland-based CDMO’s global position in the large-scale manufacturing of oncolytic as well as smallpox viruses.

 ABL credits itself with pioneering the development and manufacturing of viral vectors in the 1990s. The company said its adherent platform enables production of a substantial quantity of its oncolytic viral immunotherapy to cover the market’s requirements.  The collaboration with KaliVir dovetails with its strategy to develop its platform simultaneously on both sides of the Atlantic, it added.

In May this year, KaliVir announced a collaboration with Roche to leverage its VET platform to discover and develop novel oncolytic virus candidates.

The platform is said to be able to enhance the vaccinia viral backbone with a combination of proprietary genetic modifications to maximize tumor killing and systemic delivery and spread. Moreover, it can be readily optimized to combine with a wide variety of therapeutic transgenes.

Author: Dede Williams, Freelance Journalist

© Eraxion/iStockphoto
© Eraxion/iStockphoto

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.